{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.8","upperLimit":"7.2","value":"5.7"},{"comment":"Upper limit of 95% Confidence Interval (CI) was not estimable due to insufficient number of events.","groupId":"OG001","lowerLimit":"4.5","upperLimit":"NA","value":"6.7"},{"groupId":"OG002","lowerLimit":"6.0","upperLimit":"11.9","value":"8.2"}]}],"title":"Independent Central Review"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.8","upperLimit":"7.2","value":"5.7"},{"groupId":"OG001","lowerLimit":"4.1","upperLimit":"8.4","value":"7.2"},{"groupId":"OG002","lowerLimit":"7.1","upperLimit":"14.0","value":"9.3"}]}],"title":"Investigator Assessment"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"91"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from the date of enrollment to the earlier of the dates of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause. Progressive disease was defined as at least a 20% increase in the sum of diameters of target lesions. PFS based on independent central review and investigator assessment is reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with HER2-overexpressing(immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG000","title":"Cohort 1: HER2 Overexpressing"},{"description":"Participants with HER2-overexpressing (immunohistochemistry \\[IHC\\] 3+ or IHC 2+), unresectable and/or metastatic NSCLC adenocarcinoma who received 5.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG001","title":"Cohort 1a: HER2 Overexpressing"},{"description":"Participants with HER2-mutated, unresectable and/or metastatic NSCLC who received 6.4 mg/kg trastuzumab deruxtecan (DS-8201a).\n\nTrastuzumab deruxtecan: Antibody component covalently conjugated to a drug component, prepared by dilution based on body weight for intravenous (IV) infusion.","id":"OG002","title":"Cohort 2: HER2 Mutated"}],"paramType":"MEDIAN","populationDescription":"Progression-free survival (PFS) was assessed in the Full Analysis Set at data cut-off date of 03 May 2021.","reportingStatus":"POSTED","timeFrame":"From date of enrollment to first objective radiographic tumor progression or death from any cause,, up to 36 months (data cut-off)","title":"Progression-Free Survival (PFS) Following Treatment With DS8201a in Participants With HER2-Over-Expressing or -Mutated Non-Small-Cell Lung Cancer (NSCLC)","type":"SECONDARY","unitOfMeasure":"months"}